SUTRO BIOPHARMA INC. - COMMON STOCK
1.9900
07-2月-25 16:45:00
15 分の遅延
株式
-0.1300
-6.13%
本日の幅
1.9700 - 2.1200
ISIN
N/A
ソース
NASDAQ
-
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 1 2025 16:05:03 提供 Nasdaq GlobeNewswire
-
07 1 2025 09:00:00 提供 Nasdaq GlobeNewswire
-
10 12 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
13 11 2024 16:30:00 提供 Nasdaq GlobeNewswire
-
04 11 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
01 11 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
10 10 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 9 2024 16:01:00 提供 Nasdaq GlobeNewswire
-
14 9 2024 03:00:00 提供 Nasdaq GlobeNewswire
-
11 9 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
22 8 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
13 8 2024 16:30:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
09 7 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
13 5 2024 16:30:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
30 4 2024 08:00:01 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02 4 2024 06:18:56 提供 Nasdaq GlobeNewswire
-
25 3 2024 16:30:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
06 2 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
04 1 2024 16:05:00 提供 Nasdaq GlobeNewswire
-
14 12 2023 16:05:00 提供 Nasdaq GlobeNewswire
- <<
- <
- 1
- >